Q-omics provides the consensus-scored CDK11B profile across patient tissues and cancer cell-line models. CDK11B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDK11B is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CDK11B protein abundance shows 23,899 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where CDK11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK11B survival associations across molecular data types. CDK11B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK11B RNA expression–survival associations across cancer types. High CDK11B expression shows unfavorable associations in ACC, LGG, KICH, LUSC, LIHC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDK11B RNA expression.
This table summarizes CDK11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDK11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK11B shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, STAD, CHOL and KIRP. The HNSC box plot shows higher CDK11B RNA expression in tumor versus normal tissue (log2 FC = +0.426, t-test p < 0.001).
This table shows molecular features associated with CDK11B in patient tissues and cancer cell lines. In patient samples, CDK11B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and OESOPHAGUS.
